{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T21:06:05Z","timestamp":1776200765008,"version":"3.50.1"},"reference-count":24,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,2,1]]},"DOI":"10.1248\/bpb.b20-00580","type":"journal-article","created":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T22:07:13Z","timestamp":1612130833000},"page":"188-196","source":"Crossref","is-referenced-by-count":1,"title":["Preventive and Therapeutic Efficacy of ONO-4641, a Selective Agonist for Sphingosine 1-Phosphate Receptor 1 and 5, in Preclinical Models of Type 1 Diabetes Mellitus"],"prefix":"10.1248","volume":"44","author":[{"given":"Hiroki","family":"Shioya","sequence":"first","affiliation":[{"name":"Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd."},{"name":"Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Hiraizumi","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruto","family":"Kurata","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromu","family":"Habashita","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoyo","family":"Sato","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Nakade","sequence":"additional","affiliation":[{"name":"Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. <i>J. Biol. Chem.<\/i>, <b>279<\/b>, 20555\u201320558 (2004).","DOI":"10.1074\/jbc.R400013200"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. <i>N. Engl. J. Med.<\/i>, <b>362<\/b>, 402\u2013415 (2010).","DOI":"10.1056\/NEJMoa0907839"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. <i>FEBS Lett.<\/i>, <b>554<\/b>, 189\u2013193 (2003).","DOI":"10.1016\/S0014-5793(03)01168-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. <i>J. Biol. Chem.<\/i>, <b>277<\/b>, 21453\u201321457 (2002).","DOI":"10.1074\/jbc.C200176200"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Yanagawa Y, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer\u2019s patches by FTY720-induced lymphocyte homing. <i>Immunology<\/i>, <b>95<\/b>, 591\u2013594 (1998).","DOI":"10.1046\/j.1365-2567.1998.00639.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. <i>Science<\/i>, <b>296<\/b>, 346\u2013349 (2002).","DOI":"10.1126\/science.1070238"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. <i>Nature<\/i>, <b>427<\/b>, 355\u2013360 (2004).","DOI":"10.1038\/nature02284"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. <i>Biochem. J.<\/i>, <b>349<\/b>, 385\u2013402 (2000).","DOI":"10.1042\/bj3490385"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Lo CG, Xu Y, Proia RL, Cyster JG. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. <i>J. Exp. Med.<\/i>, <b>201<\/b>, 291\u2013301 (2005).","DOI":"10.1084\/jem.20041509"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG, Coughlin SR. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. <i>Science<\/i>, <b>316<\/b>, 295\u2013298 (2007).","DOI":"10.1126\/science.1139221"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) van Doorn R, Lopes Pinheiro MA, Kooij G, Lakeman K, van het Hof B, van der Pol SM, Geerts D, van Horssen J, van der Valk P, van der Kam E, Ronken E, Reijerkerk A, de Vries HE. Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. <i>J. Neuroinflammation<\/i>, <b>9<\/b>, 133 (2012).","DOI":"10.1186\/1742-2094-9-133"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Forrest M, Sun SY, Hajdu R, <i>et al.<\/i> Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated <i>via<\/i> distinct receptor subtypes. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>309<\/b>, 758\u2013768 (2004).","DOI":"10.1124\/jpet.103.062828"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, Rosen H. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. <i>J. Biol. Chem.<\/i>, <b>279<\/b>, 13839\u201313848 (2004).","DOI":"10.1074\/jbc.M311743200"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kurata H, Kusumi K, Otsuki K, Suzuki R, Kurono M, Komiya T, Hagiya H, Mizuno H, Shioya H, Ono T, Takada Y, Maeda T, Matsunaga N, Kondo T, Tominaga S, Nunoya K, Kiyoshi H, Komeno M, Nakade S, Habashita H. Discovery of a 1-methyl-3,4-dihydronaphthalene-based sphingosine-1-phosphate (S1P) receptor agonist ceralifimod (ONO-4641). A S1P<sub>1<\/sub> and S1P<sub>5<\/sub> selective agonist for the treatment of autoimmune diseases. <i>J. Med. Chem.<\/i>, <b>60<\/b>, 9508\u20139530 (2017).","DOI":"10.1021\/acs.jmedchem.7b00785"},{"key":"15","unstructured":"15) Zipp F, Vollmer T, Bar-Or A, Due B, Thangavelu K, Fischer TZ, Selmaj K. Relapse rates in patients with multiple sclerosis receiving ONO-4641, a sphingosine-1-phosphate receptor-1 and -5 agonist: interim results from an extension of the DreaMS study. <i>Mult. Scler. J.<\/i>, <b>19<\/b>, (S1) 74\u2013558, P992 (2013): \u2039https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458513502429\u203a, accessed 29 March, 2020."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Katsarou A, Gudbj\u00f6rnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, Jacobsen LM, Schatz DA, Lernmark \u00c5. Type 1 diabetes mellitus. <i>Nat. Rev. Dis. Primers<\/i>, <b>3<\/b>, 17016 (2017).","DOI":"10.1038\/nrdp.2017.16"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Maki T, Gottschalk R, Ogawa N, Monaco AP. Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. <i>Transplantation<\/i>, <b>79<\/b>, 1051\u20131055 (2005).","DOI":"10.1097\/01.TP.0000161220.87548.EE"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Komiya T, Sato K, Shioya H, Inagaki Y, Hagiya H, Kozaki R, Imai M, Takada Y, Maeda T, Kurata H, Kurono M, Suzuki R, Otsuki K, Habashita H, Nakade S. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. <i>Clin. Exp. Immunol.<\/i>, <b>171<\/b>, 54\u201362 (2013).","DOI":"10.1111\/j.1365-2249.2012.04669.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Penaranda C, Tang Q, Ruddle NH, Bluestone JA. Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. <i>Diabetes<\/i>, <b>59<\/b>, 1461\u20131468 (2010).","DOI":"10.2337\/db09-1129"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. <i>Diabetes<\/i>, <b>43<\/b>, 667\u2013675 (1994).","DOI":"10.2337\/diabetes.43.5.667"},{"key":"21","unstructured":"21) Miyazaki A, Hanafusa T, Yamada K, Miyagawa J, Fujino-Kurihara H, Nakajima H, Nonaka K, Tarui S. Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study. <i>Clin. Exp. Immunol.<\/i>, <b>60<\/b>, 622\u2013630 (1985)."},{"key":"22","unstructured":"22) van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. <i>Physiol. Rev.<\/i>, <b>91<\/b>, 79\u2013118 (2011)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kappos L, Antel J, Comi G, Montalban X, O\u2019Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. Oral fingolimod (FTY720) for relapsing multiple sclerosis. <i>N. Engl. J. Med.<\/i>, <b>355<\/b>, 1124\u20131140 (2006).","DOI":"10.1056\/NEJMoa052643"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. <i>N. Engl. J. Med.<\/i>, <b>362<\/b>, 387\u2013401 (2010).","DOI":"10.1056\/NEJMoa0909494"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/2\/44_b20-00580\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T04:32:35Z","timestamp":1612585955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/2\/44_b20-00580\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b20-00580","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}